Calliditas Therapeutics AB
https://www.calliditas.se/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Calliditas Therapeutics AB
Novartis Bookends October With Two IgAN Successes
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.
Hanmi’s GLP-1 Obesity Contender Gets Phase III Nod In Korea
Hanmi aims to commercialize its GLP-1 obesity treatment, the first one from its ambitious HOP project, within three years as it moves to Phase III in Korea.
Accelerated Approvals: Conversions Still Outweigh Withdrawals, But Takeda’s Exkivity Brings 2023’s Pull Count To Six
US FDA’s Oncologic Drugs Advisory Committee will convene in November for a ‘general discussion about delayed confirmatory trials’ and the ‘continued optimization of the accelerated approval process.’
Muted APPLAUSE For Novartis In IgAN
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Pharmalink AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice